wtx-124
·Code: WTX-124
wtx-124: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | Phase 1 |
Clinical Trials (1)
A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors
FDA Decisions
FDA_Meeting18 mg was accepted as the recommended dose to move forward in development, and the FDA provided initial guidance for a monotherapy WTX-124 registration path in post-ICI advanced melanoma.(HOWL)
Frequently asked questions
Who is developing wtx-124?
wtx-124 is being developed by Werewolf Therapeutics, Inc..
How many clinical trials involve wtx-124?
BioSniper tracks 1 clinical trial involving wtx-124.
What is wtx-124's latest FDA decision?
The most recent tracked FDA decision for wtx-124 is FDA_Meeting for 18 mg was accepted as the recommended dose to move forward in development, and the FDA provided initial guidance for a monotherapy WTX-124 registration path in post-ICI advanced melanoma..
Get deeper analysis on wtx-124
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis